mTNBC Unicorns: Living In Contradiction
Becoming a cancer “unicorn”--a person whose cancer responds exceptionally well to available treatment and who survives beyond what is expected--is what most of us hope for. This is all the more true for triple negative MBC where effective, targeted treatments are still sorely lacking. Today we talk to two women who have lived with triple negative metastatic breast cancer for 8 years. Dr. Toni Willis and Colleen Broughton share their diagnosis & treatment stories, including their experiences with second opinions, clinical trials, self-advocacy, and cultivating joy for themselves & their families as they navigate surviving longer than they –or their doctors—expected to.
Report Back From ASCO 2023: What’s the Latest News in MBC Research?
Dr. Sherry Shen, breast oncologist from Memorial Sloan Kettering Cancer Center, breaks down the recent research from the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. She will present new findings in Metastatic Breast Cancer research.
OMBCL Shorts #2: Dr. Erika Hamilton with Top Takeaways from ASCO23
Our second OMBCL Shorts features Dr. Erika Hamilton answering questions about her top takeaways from ASCO23. In this 20-minute interview we covered important updates on the CDK4/6 inhibitors for both early-stage and metastatic breast cancer, as well as research on a new HER3 ADC and the first AKT inhibitor for MBC.
OMBCL Shorts #1: Dr. Stephanie Graff & Her Steps For Those Newly Diagnosed MBC
Our inaugural OMBCL Shorts features Dr. Stephanie Graff talking about what she does when someone is newly diagnosed with MBC. This season, we had a 3-part series for people newly diagnosed and we couldn't resist getting her take on the topic. And we're so glad we asked!
Recent Advances, Controversies, and Emerging Trends in MBC
Over the last 20 years, advances in HER2 targeting treatments, antibody-drug conjugates (ADCs), immune checkpoint inhibitors (ICIs), and cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have prolonged survival and changed the breast cancer treatment landscape. Success leads to more questions about optimal drug sequencing, mechanisms of resistance, and how to overcome that resistance. Let’s ask Dr. Stephanie Graff to help us tackle these topics and more.
Report Back from ASCO 2022: What’s the Latest in MBC Research?
The biggest cancer conference in the world, the American Society of Clinical Oncology (ASCO) 2022 annual meeting, was back in person after 2 years online during the COVID pandemic. Some of the research highlights presented this year are “practice-changing.” and received a rarely given standing ovation. What is practice changing in MBC? Get the answer to this question and a lot more in the report back from ASCO
Dr. Nancy Lin: Are CNS Mets Becoming More Treatable? What’s New with STOP-HER2?
Brain metastases are unfortunately an all too common and devastating complication of breast cancer. The blood-brain barrier has long been a key obstacle to developing effective systemic therapies; however, newer agents are showing signs of overcoming this challenge. Dr. Nancy Lin explains.
Dr. Priya Kumthekar: Glimpses of Hope for Leptomeningeal Metastases
Co-hosts Victoria Goldberg and Dr. Paula Jayne sit down with neuro-oncologist Dr. Priya Kumthekar to talk about leptomeningeal metastases: what they are, how are they treated, and what research is upcoming, including a discussion on ANGled, the new Phase 3 trial for MBC patients newly diagnosed with leptomeningeal metastases.
Dr. Timothy Pluard: the Future of MBC Care is Already Here
The future of personalized care for those living with MBC is already here, and it is happening in Kansas City, Missouri. Dr. Timothy Pluard, Medical Director of the Kansas City’s Saint Luke’s Koontz Center for Advanced Breast Cancer is with us today and we’ll ask him how he and his team create an individualized, completely comprehensive plan for each woman.
Report Back from SABCS 2021: What’s the Latest in MBC Research?
Learn about the most recent information released at the annual San Antonio Breast Cancer Symposium regarding metastatic breast cancer research with Dr. Peter Schmid, Professor of Cancer Medicine at Barts Cancer Institute in London, England. Dr. Schmid will provide a comprehensive update and answer your questions about these new developments.
MBC101 - what happens when MBC spreads to the brain?
On 10/12/21 Lianne Kraemer, an MBC patient advocate living with brain mets , and SHARE hosted two brilliant young clinicians from Moffitt in a discussion on management of breast cancer brain metastases. Today we are bringing you this webinar with our additional commentary. We will let you in on a little secret. This episode is a glimpse into how we envision the next season’s Road to a Cure. It will include more content with an educational angle for the newly diagnosed or those who are ready to take a deeper dive with us into the basics. We call it MBC101.
Road to a Cure - drug resistance
It is fitting that our 7th and last stop before the SABCS is back to NYC. Co-hosts Lisa Laudico and Ellen Landsberger talk with Dr Sarat Chandarlapaty, a leading Physician Scientist at MSKCC. As both a physician treating patients and a scientist in the lab, Dr. Chandarlapaty gives us an understanding of translational medicine, transferring what he learns from his patients back into the lab to answer questions that advance the treatment of metastatic breast cancer.
Road to a Cure - ADC & SARM
How famous is Dr Hope Rugo? She belongs to a tiny elite group of oncologists who have their own Wikipedia page. Dr. Dennis Slamon is quite possibly the only other member. Enough said. No surprise that we can’t wait to hear what she has to say about a new class of drugs, known as ADCs and specifically, the first ADC for mTNBC that already has a nickname – Sassy (sacituzumab govitecan). Do you know what a SARM is? It is a special class of drugs for those who are Androgen Receptor (AR) positive. Listen and find out.
Road to a Cure - use of immunotherapy
This week we are visiting Dr Stephanie Goff at the NIH in Bethesda, Maryland. Dr Goff is a surgical oncologist and a senior member of a research team led by Dr. Steven A. Rosenberg, a man widely regarded as the father of immunotherapy. A friend, who knows a thing or two about this place. is joining us on this trip. Her name is Judy Perkins, and she is the first MBC patient who has been cured by a revolutionary immunotherapy treatment, known as adoptive cell therapy, that was administered by Dr Goff and her colleagues at the NCI.
Road to a Cure - Dr. Heather Parsons & Dr. Nancy Lin
The Road to a Cure series heads to Boston to have Senior Producer and Co-host, Victoria Goldberg and co-host Dr. Paula Jayne speak with Dr. Nancy Lin and Dr. Heather Parsons about the possibilities and the current barriers to considering a cure for HER2+ MBC. Dr. Parsons and Dr. Lin are medical oncologists and professors at Harvard Medical School. Dr. Lin is also the Director of the Metastatic Breast Cancer Program and the Associate Chief of the Division of Breast Oncology at Dana Farber Cancer Institute. While an amazing gift, long-term survival among some HER2+ patients can also sometimes bring special challenges. Given the higher prevalence of brain metastases among HER2+ patients, Drs. Lin and Parsons also discuss current research on brain mets, along with areas of promising overall MBC research for each subtype.
Road to a Cure - Dr. Sara Hurvitz
The Road to a Cure series gets on the redeye to LA to have Senior Producer and Co-host, Victoria Goldberg and co-host Kate Pfitzer speak with Dr. Sara Hurvitz. She talks about her perspective on where we are as we work for a cure, the HER2+ studies she is excited about, and other research that is intriguing as it relates to all subtypes
Report Back from ASCO: What’s the Latest in Metastatic Breast Cancer
Are you living with ER+/HER2- or TNBC MBC and tired of hearing about new HER2 therapies and wondering when it will be your turn? Just after the meeting SHARE welcomed Dr. Timothy Pluard from University of Missouri-KC School of Medicine to a webinar highlighting promising data from trials and labs across the globe presented at the this year’s meeting,
Report back from SABCS
Welcome to this bonus episode of Our MBC Life. It feels like a lifetime ago, but just a few weeks ago the world's largest breast cancer conference, the San Antonio Breast Cancer Symposium, was held. Just after the symposium SHARE welcomed Dr. Neil Iyengar from Memorial Sloan Kettering to a webinar where he shared information from SABCS highlighting both early-stage and metastatic research.
Just Gotta SHARE - Trailblazer
After her TNBC early stage diagnosis our October Trailblazer, Tiah Tomlin, wanted to be a part of the solution. Hear how she did that with her non-profit organization which is “dedicated to providing a cancer educational program and hands-on supportive services to build confidence in people of all ages, leading to a better quality of life.”
Ricki Fairley and TOUCH, The Black Cancer Alliance
Ricki Fairley, founder of TOUCH, the Black Breast Cancer Alliance, shares her incredible story of how she upended and changed her life and ended her successful marketing career when she was diagnosed Stage 3A Triple Negative Breast Cancer . Ricki talks about the founding of her organization and her overall goal to address Black Breast Cancer as a unique and special disease state, with the overall goal of reducing the mortality rate for Black women.